Clinical Development of CT327, a novel treatment for childhood Atopic Dermatitis

点击翻译按钮获取中文摘要

The CT327 Atopic Dermatitis (AD) project aims to further develop Creabilis' novel topical treatment for AD in children. Creabilis is a clinical stage biotech company developing drugs in dermatology, with a team experienced in bringing new drugs to market. We intend to further develop CT327 in childhood AD, an area of significant and often neglected unmet medical need, demanding effective, but safer drugs. We believe CT327 will meet these needs. CT327 has a novel MoA and will treat all symptoms of AD, including the itch component of the disease that has the greatest impact on quality of life. Developed using Creabilis’ Low Systemic Exposure (LSE) technology, CT327 has a favourable safety profile in the 5 clinical studies carried out to date. TSB funding will allow Creabilis to complete a Phase 2b AD study in children that will definitively demonstrate the safety and efficacy characteristics that will allow CT327 to be positioned as a novel long-term topical treatment for childhood AD.